Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor

Photodiagnosis and Photodynamic Therapy

Volumn 12, Issue 1, 2015, Pages 19-26

  Fateye, Babasola ^a   Wan, Aaron ^a   Yang, Xue ^a   Myers, Kenneth ^b   Chen, Bin ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Apoptosis; LY294002; Phosphatidylinositol 3 kinase (PI3K) inhibitor; Photodynamic therapy (PDT); Verteporfin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; VERTEPORFIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MALE; MITOCHONDRION; MOUSE; MTS ASSAY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY; TUMOR CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; METABOLISM; PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION RESPONSE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL SURVIVAL; CHROMONES; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84924853276     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.01.004     Document Type: Article

References (37)

1. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
2. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 2006, 16:279-305.
3. Granville D.J., Shaw J.R., Leong S., Carthy C.M., Margaron P., Hunt D.W., et al. Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis. Am J Pathol 1999, 155:1021-1025.
4. Li Z., Agharkar P., Chen B. Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function. Cancer Lett 2013, 339:128-134.
5. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin Cancer Res 2006, 12:917-923.
6. Khurana M., Moriyama E.H., Mariampillai A., Wilson B.C. Intravital high-resolution optical imaging of individual vessel response to photodynamic treatment. J Biomed Opt 2008, 13:040502.
7. Petermeier K., Tatar O., Inhoffen W., Volker M., Lafaut B.A., Henke-Fahle S., et al. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 2006, 90:1034-1039.
8. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005, 61:1216-1226.
9. Samkoe K.S., Chen A., Rizvi I., O'Hara J.A., Hoopes P.J., Pereira S.P., et al. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int J Radiat Oncol Biol Phys 2010, 76:251-259.
10. Huggett M.T., Jermyn M., Gillams A., Illing R., Mosse S., Novelli M., et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer 2014, 110:1698-1704.
11. Nowak-Sliwinska P., van Beijnum J.R., van Berkel M., van den Bergh H., Griffioen A.W. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010, 13:281-292.
12. Chen B., Roskams T., de Witte P.A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol 2002, 76:509-513.
13. Koudinova N.V., Pinthus J.H., Brandis A., Brenner O., Bendel P., Ramon J., et al. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 2003, 104:782-789.
14. Chen B., Crane C., He C., Gondek D., Agharkar P., Savellano M.D., et al. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy. Int J Cancer 2008, 123:695-701.
15. Fateye B., Li W., Wang C., Chen B. Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells. Photochem Photobiol 2012, 88:1265-1272.
16. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
17. Zhuang S., Kochevar I.E. Singlet oxygen-induced activation of Akt/protein kinase B is independent of growth factor receptors. Photochem Photobiol 2003, 78:361-371.
18. Zhuang S., Ouedraogo G.D., Kochevar I.E. Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases. Oncogene 2003, 22:4413-4424.
19. Volanti C., Hendrickx N., Van Lint J., Matroule J.Y., Agostinis P., Piette J. Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy. Oncogene 2005, 24:2981-2991.
20. Bozkulak O., Wong S., Luna M., Ferrario A., Rucker N., Gulsoy M., et al. Multiple components of photodynamic therapy can phosphorylate akt. Photochem Photobiol 2007, 83:1029-1033.
21. Matsubara A., Nakazawa T., Noda K., She H., Connolly E., Young T.A., et al. Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model. Invest Ophthalmol Vis Sci 2007, 48:4741-4747.
22. Koon H.K., Chan P.S., Wong R.N., Wu Z.G., Lung M.L., Chang C.K., et al. Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem 2009, 108:1356-1363.
23. Dewaele M., Martinet W., Rubio N., Verfaillie T., de Witte P.A., Piette J., et al. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J Cell Mol Med 2011, 15:1402-1414.
24. Kessel D., Vicente M.G., Reiners J.J. Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg Med 2006, 38:482-488.
25. Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007, 67:5840-5850.
26. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
27. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008, 1784:159-185.
28. Fateye B., Li W., Wang C., Chen B. Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells. Photochem Photobiol 2012, 10.1111/j.1751-1097.2012.01160.x.
29. Granville D.J., Jiang H., An M.T., Levy J.G., McManus B.M., Hunt D.W. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br J Cancer 1999, 79:95-100.
30. Granville D.J., Jiang H., An M.T., Levy J.G., McManus B.M., Hunt D.W. Overexpression of Bcl-X(L) prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA. FEBS Lett 1998, 422:151-154.
31. Fernald K., Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol 2013, 23:620-633.
32. Aveline B.M., Hasan T., Redmond R.W. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B 1995, 30:161-169.
33. Rizvi I., Anbil S., Alagic N., Celli J., Zheng L.Z., Palanisami A., et al. PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D ovarian cancer model. Photochem Photobiol 2013, 89:942-952.
34. Gomer C.J., Rucker N., Murphree A.L. Differential cell photosensitivity following porphyrin photodynamic therapy. Cancer Res 1988, 48:4539-4542.
35. Triesscheijn M., Ruevekamp M., Aalders M., Baas P., Stewart F.A. Comparative sensitivity of microvascular endothelial cells, fibroblasts and tumor cells after in vitro photodynamic therapy with meso-tetra-hydroxyphenyl-chlorin. Photochem Photobiol 2004, 80:236-241.
36. Moore R.B.X., Tulip Z., Chapman J.J.D. A comparison of susceptibility to photodynamic treatment between endothelial and tumor cells in vitro and in vivo. Photodiagn Photodyn Ther 2007, 4:160-169.
37. Weiss A., van Beijnum J.R., Bonvin D., Jichlinski P., Dyson P.J., Griffioen A.W., et al. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med 2014, 18:480-491.